Patents by Inventor Jyothsna Ravula
Jyothsna Ravula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11622967Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: GrantFiled: August 1, 2018Date of Patent: April 11, 2023Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Vijay Sidram Benade, Saivishal Daripelli, Pradeep Jayarajan, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20220409614Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patient with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist, masupirdine or a pharmaceutically acceptable salt thereof either alone or in combination with an acetylcholinesterase inhibitor such as donepezil and NMDA (N-Methyl-D-aspartate) receptor antagonist, memantine. The present invention further provides use of the said compound in the manufacture of a medicament and pharmaceutical compositions comprising the said compounds intended for the treatment of the disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: December 29, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Satish JETTA, Raghava Chowdary PALACHARLA, Santosh Kumar PANDEY, Abdul Rasheed MOHAMMED, Vijay Sidram BENADE, Vinod Kumar GOYAL, Ramkumar SUBRAMANIAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Publication number: 20220387451Abstract: The present invention relates to a pharmaceutical composition comprising solid dispersion of amorphous abiraterone acetate and one or more pharmaceutically acceptable excipients, having improved solubility, stability, bioavailability, and no positive food effect. The present invention also relates to a method for its preparation, a dosage form comprising such compositions, and the use of the said composition or dosage form as a medicament for the treatment of prostate cancer.Type: ApplicationFiled: November 13, 2020Publication date: December 8, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Dhanunjay Kumar DOGIPARTI, Koteshwara MUDIGONDA, Jyothsna RAVULA, Venkateswarlu JASTI
-
Publication number: 20210213026Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: August 1, 2018Publication date: July 15, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Vijay Sidram BENADE, Saivishal DARIPELLI, Pradeep JAYARAJAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 9636335Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: GrantFiled: June 10, 2015Date of Patent: May 2, 2017Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kambhampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20150283125Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: ApplicationFiled: June 10, 2015Publication date: October 8, 2015Applicant: SUVEN LIFE SCIENCES LTDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Suresh YARLAGADDA, Srinivasa Rao RAVELLA, Anil Karbhari SHINDE, Ramasastri KAMBHAMPATI, Praveen Kumar ROAYAPALLEY, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Sriramachandra Murthy PATNALA, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 9079894Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: GrantFiled: January 5, 2012Date of Patent: July 14, 2015Assignee: SUVEN LIFE SCIENCES LTDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kambhampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20140187581Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.Type: ApplicationFiled: January 5, 2012Publication date: July 3, 2014Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kamphampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
-
Patent number: 8598204Abstract: The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.Type: GrantFiled: December 29, 2009Date of Patent: December 3, 2013Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Ishtiyaque Ahmad, Pradeep Jayarajan, Nagaraj Vishwottam Kandikere, Anil Karbhari Shinde, Rama Sastri Kambhampati, Gopinadh Bhyrapuneni, Jyothsna Ravula, Sriramachandra Murthy Patnala, Venkateswarlu Jasti
-
Patent number: 8551718Abstract: The present invention provides novel functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT2A, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.Type: GrantFiled: March 31, 2010Date of Patent: October 8, 2013Assignee: Suven Life Science LimitedInventors: Ishtiyaque Ahmad, Reddy Venkat Mekala, Reddy Muddukrishna Chillakur, Ramkumar Subramaniam, Jyothsna Ravula, Sriramachandra Murthy Patnala, Ramakrishna Nirogi, Venkateswarlu Jasti
-
Publication number: 20120315657Abstract: The present invention provides novel functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT2A, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.Type: ApplicationFiled: March 31, 2010Publication date: December 13, 2012Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ishtiyaque Ahmad, Reddy Venkat Mekala, Reddy Muddukrishna Chillakur, Ramkumar Subramaniam, Jyothsna Ravula, Sriramachandra Murthy Patnala, Ramakrishna Nirogi, Venkateswarlu Jasti
-
Publication number: 20120277216Abstract: The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.Type: ApplicationFiled: December 29, 2009Publication date: November 1, 2012Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Ishtiyaque Ahmad, Pradeep Jayarajan, Nagaraj Vishwottam Kandikere, Anil Karbhari Shinde, Rama Sastri Kambhampati, Gopinadh Bhyrapuneni, Jyothsna Ravula, Sriramachandra Murthy Patnala, Venkateswarlu Jasti